NIAID-VRC- Rapid Manufacturing Response

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: DAVID  LINDSAY
Organization: LEIDOS BIOMEDICAL RESEARCH, INC.
Fiscal Year: 2022
Award: $9,822,408
Funding agency: National Institute of Allergy and Infectious Diseases

The Vaccine Research Center (VRC) mission and scope includes rapidly moving clinical candidates from the research bench through development and GMP manufacturing to the clinic. The VRC is exploring a wide range of initiatives, including but not limited to new technologies which would decrease the time between candidate discovery and first-in-human clinical trials. These initiatives will allow VRC and NIAID to quickly assess clinical stage products for safety and efficacy and to expedite the production and supply of investigational products to the field during public health emergencies.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Antibodies><COVID-19 virus><COVID19 virus><Clinic><Clinical><Clinical Trials><CoV-2><CoV2><Development><HIV><Human Immunodeficiency Viruses><Investigation><LAV-HTLV-III><Lymphadenopathy-Associated Virus><Mission><NIAID><National Institute of Allergy and Infectious Disease><Phase><Process><Production><Research><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Testing><Time><Vaccine Research><Vaccines><Virus-HIV><Wuhan coronavirus><clinical candidate><coronavirus disease 2019 virus><coronavirus disease-19 virus><developmental><first in man><first-in-human><flu><hCoV19><nCoV2><new technology><novel technologies><public health emergency><response>